Latest Breaking News On - Rnas the company or regulus - Page 1 : vimarsana.com

Regulus Therapeutics (RGLS) Enters $100M Oversubscribed Private Placement

Regulus Therapeutics (RGLS) Enters $100M Oversubscribed Private Placement
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCanaccord genuityRegulus therapeutics incHc wainwright coEnterprise associatesRnas the company or regulusRegulus therapeuticsDeep track capitalFederated hermes kaufmann fundsNew enterprise associatesOctagon capitalCommon stockSecurities act

Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity

SAN DIEGO, March 12, 2024 /PRNewswire/ Regulus Therapeutics Inc. , a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs , today.

San diegoUnited statesCanaccord genuityHc wainwright coPrnewswire regulus therapeutics incRnas the company or regulusEnterprise associatesExchange commissionRegulus therapeutics incDeep track capitalFederated hermes kaufmann fundsNew enterprise associatesOctagon capitalCommon stockSecurities actPrivate securities litigation reform act

Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Mechanistic dose response observed at a 2mg/kg dose level based on urinary biomarker analyses Encouraging exploratory results of imaging-based biomarkers with greatest reductions in total kidney.

United statesSan diegoJay haganAlan yuPreston klassenRnas the company or regulusUniversity of kansas medical centerExchange commissionRegulus therapeutics incPrnewswire regulus therapeutics incHead of research development regulusKansas medicalDominant polycystic kidney diseasePrivate securities litigation reform act

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesJay haganRnas the company or regulusExchange commissionRegulus therapeutics incRegulus therapeuticsDominant polycystic kidney diseasePrivate securities litigation reform act

Regulus Therapeutics Announces Completion Of Enrollment In Third Cohort Of Phase 1B Multiple-Ascending Dose (MAD) Clinical Trial Of RGLS8429 For The T

Regulus Therapeutics Announces Completion Of Enrollment In Third Cohort Of Phase 1B Multiple-Ascending Dose (MAD) Clinical Trial Of RGLS8429 For The T
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesJay haganRnas the company or regulusRegulus therapeutics incDominant polycystic kidney disease